MENU
+Compare
RLMD
Stock ticker: NASDAQ
AS OF
Jul 1 closing price
Price
$0.62
Change
+$0.02 (+3.33%)
Capitalization
20.45M

RLMD Relmada Therapeutics Forecast, Technical & Fundamental Analysis

Relmada Therapeutics Inc is a clinical-stage biotechnology company... Show more

RLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for RLMD with price predictions
Jul 01, 2025

RLMD's RSI Oscillator ascending out of oversold territory

The RSI Indicator for RLMD moved out of oversold territory on June 26, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In of the 32 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where RLMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

RLMD moved above its 50-day moving average on June 26, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where RLMD advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

RLMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 208 cases where RLMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RLMD as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for RLMD turned negative on June 12, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.888) is normal, around the industry mean (16.395). P/E Ratio (0.000) is within average values for comparable stocks, (58.556). RLMD's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.311). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (259.528).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RLMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
RLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

RLMD is expected to report earnings to fall 31.03% to -40 cents per share on August 12

Relmada Therapeutics RLMD Stock Earnings Reports
Q2'25
Est.
$-0.40
Q1'25
Missed
by $0.21
Q4'24
Beat
by $0.09
Q3'24
Missed
by $0.04
Q2'24
Beat
by $0.24
The last earnings report on May 12 showed earnings per share of -57 cents, missing the estimate of -37 cents. With 183.99K shares outstanding, the current market capitalization sits at 20.45M.
A.I. Advisor
published General Information

General Information

a clinical-stage biotechnology company, which engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2222 Ponce de Leon Boulevard
Phone
+1 786 629-1376
Employees
20
Web
https://www.relmada.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ETD29.351.50
+5.39%
Ethan Allen Interiors
ODFL168.456.15
+3.79%
Old Dominion Freight Line
GENK4.030.13
+3.33%
GEN Restaurant Group
CRC46.110.44
+0.96%
California Resources Corp
PRPL0.740.01
+0.89%
Purple Innovation

RLMD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RLMD has been loosely correlated with SYRE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if RLMD jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLMD
1D Price
Change %
RLMD100%
+2.63%
SYRE - RLMD
36%
Loosely correlated
+3.47%
ENTO - RLMD
36%
Loosely correlated
-2.37%
PRTC - RLMD
31%
Poorly correlated
N/A
AVXL - RLMD
31%
Poorly correlated
+1.19%
ZVRA - RLMD
29%
Poorly correlated
+1.59%
More